entertainment -WSS

entertainment

author：knowledge 2025-09-02 08:14:09 - browse：7

The future looks even brighter for the blockbuster Enhertu, showcased here at ASCO. ADAM FEUERSTEIN/STAT

CHICAGO — The cancer drug Enhertu stalled the growth of tumors by more than a year, significantly longer than standard chemotherapy did in women with the most common form of metastatic breast cancer — a clinical trial result that once again promises to rewrite the rules for the treatment of the disease.

The makers of Enhertu, Daiichi Sankyo and AstraZeneca, said the new data, if cleared by regulators, could shift the way physicians treat hormone receptor-positive, metastatic breast cancer, and create a new standard of care in which patients with breast tumors that express even the faintest amount of HER2 protein can benefit.

“It’s not an overestimation to say that trastuzumab deruxtecan is the most potent drug ever developed for breast cancer,” said Paolo Tarantino, a medical oncologist at the Dana-Farber Cancer Institute, using the scientific name for Enhertu. “It does come with side effects that we’re learning to manage, but with that said, I’ve never seen data like what’s being reported here.”

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： DIEP, the 'gold standard' of breast reconstruction, is under threat
Next article： STAT letters to the editor on burnt

WSS

Pfizer plans to depart BIO

Supreme Court wrestles with OxyContin maker's bankruptcy deal

Spinal cord stimulation reduces pain in amputees, study finds

New Ultima Genomics DNA sequencer can read genome for $100

What causes an itch? Researchers may have solved the mystery

Woodcock on FDA’s accelerated approval and her next chapter

knowledge

entertainment

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

entertainment

What does generative AI mean for health care? We asked experts

Readout Newsletter: Vertex, Biogen's Aduhelm, and Bristol updates

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

SAMSHA loosens regulations on methadone treatment centers

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Radiology is caught between AI's potential and concern for patients

23andMe had bad news about my health. I wish a person had delivered it

Chemotherapy shortages won’t get better under Biden’s latest plan

Peter Hotez and the public health issue of online harassment

Even great ERs can’t make up for American health disparities

Wikipedia

AI models in health care face new federal disclosure requirements

AI models in health care face new federal disclosure requirements

What we need to know about Arena Bioworks

Why sickle cell disease is getting the first CRISPR treatment

Vertex non

The woman behind the Dana Farber

Wikipedia

focus

leisure time

leisure time